FibroGen to Present at Upcoming Investor Conferences

Rhea-AI Summary

FibroGen, a biopharmaceutical company, announced CEO Enrique Conterno's participation in virtual healthcare conferences on September 9 and September 16, 2020. He will speak at the Citigroup 15th Annual BioPharma Conference at 2:25 PM ET and the Morgan Stanley 18th Annual Global Healthcare Conference at 3:30 PM ET. A live audio webcast can be accessed on the FibroGen Investor webpage, with replays available for 30 days. FibroGen focuses on developing innovative treatments for unmet medical needs, including roxadustat for chronic kidney disease anemia and pamrevlumab for various conditions.

SAN FRANCISCO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences:

• Citigroup 15th Annual BioPharma Conference on September 9, 2020 at 2:25 PM Eastern Time
• Morgan Stanley 18^th Annual Global Healthcare Conference on September 16, 2020 at 3:30 PM Eastern Time

A live audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at https://fibrogen.gcs-web.com/.  A replay will be available for approximately 30 days.

About FibroGen

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19). For more information, please visit www.fibrogen.com.

Contact:
FibroGen, Inc.

Media Inquiries:
Sara Iacovino
1.703.474.4452
sara.iacovino@gcihealth.com

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
1.415.630.0131
mtung@fibrogen.com

FAQ

What conferences will FibroGen participate in during September 2020?

FibroGen will participate in the Citigroup 15th Annual BioPharma Conference on September 9, 2020, and the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020.

What time will the Citigroup BioPharma Conference presentation start?

The Citigroup 15th Annual BioPharma Conference presentation will start at 2:25 PM Eastern Time.

Where can I watch the FibroGen conference presentations?

You can watch the FibroGen conference presentations on the Events & Presentations section of their Investor webpage.

What is Roxadustat and its purpose?

Roxadustat is an oral small molecule inhibitor developed by FibroGen to treat anemia associated with chronic kidney disease.

What other conditions is Pamrevlumab being developed for?

Pamrevlumab is in clinical development for idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer, Duchenne muscular dystrophy, and COVID-19.